Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEV90 of liposomal bupivacaine for interscalene block after rotator cuff repair
ChiCTR2400085466Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bupivacaine in Rotator cuff deficiency (RCD), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: 24-hour analgesic effect. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
Rotator cuff deficiency (RCD)
Beyond the preview
Go deeper on ChiCTR2400085466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085466.